Ketamine for PTSD: What Research and Current Guidelines Say

Ketamine is being studied for post-traumatic stress disorder, but it is not an established, guideline-recommended PTSD treatment. The current VA/DoD guideline suggests against ketamine for PTSD. People seeking relief deserve to hear that recommendation alongside research headlines and to discuss treatments with stronger supporting evidence.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

Why do studies sometimes sound encouraging?

Some small studies have reported improvements after intravenous ketamine. A 2021 randomized trial in 30 adults found reduced PTSD symptom severity compared with an active control. A larger 2022 trial involving 158 veterans and service members did not show a significant advantage on the main PTSD symptom measures. Different populations and designs can produce different findings.

These studies do not establish a compounded at-home spray as an effective PTSD treatment. They also cannot show that every patient benefits or that any benefit persists indefinitely. The guideline considers the overall evidence and potential harms rather than a single positive result.

Which PTSD treatments are recommended?

The VA/DoD guideline prioritizes specific trauma-focused psychotherapies, including Cognitive Processing Therapy, Prolonged Exposure, and Eye Movement Desensitization and Reprocessing. Certain medications are also recommended options. Discuss availability, your preferences, previous experiences, and whether a therapist has training in the approach being offered.

What if I also have depression?

PTSD and depression can occur together, but they require separate assessment and treatment goals. A treatment considered for depression should not be presented as proven PTSD care. Ask which diagnosis a proposed medication is intended to address and how changes in each condition will be tracked.

What if previous treatment has not helped enough?

A clinician can review what you tried, for how long, whether side effects limited treatment, and whether another recommended therapy or medication is appropriate. An incomplete response does not mean you have failed or must choose an experimental option. Do not stop current care without discussing the next step.

• Which symptoms are we targeting?
• What recommended PTSD options have I not yet tried?
• How would we measure meaningful improvement?
• Who will coordinate care if I have depression, substance use, or sleep concerns?

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: VA/DoD: current PTSD guideline; VA: trauma-focused psychotherapy; 2021 randomized infusion trial; 2022 veteran and service-member trial; FDA: compounded-drug risks.